Table 4.
Disease free survival in the overall study population (N:270) and in patients with a minimum of 24-month follow-up (N:129).
| 2yr DFS (%) (SE) |
mDFS (95% CI) |
p value | HR (95% CI) | |
|---|---|---|---|---|
| N:270 | ||||
| 62.0 (0.04) | NR | |||
|
Nodal status
Positive Negative |
46.6 (0.06) 77.7 (0.05) |
18 (3-33) NR |
<0.0001 | 3.127 (1.935-5.054) |
|
Size of residual breast disease
ypT3/4 ypT1/2 |
39.4 (0.12) 63.6 (0.04) |
10 (4-16) NR |
0.002 | 2.623 (1.383-8.976) |
|
Grading
3 1/2 |
58.3 (0.04) 85.9 (0.06) |
32 (27-38) NR |
0.02 | 2.720 (1.100-6.727) |
|
Ki67
>20 ≤20 |
58.8 (0.04) 83.2 (0.07) |
32 (26-38) NR |
0.02 | 2.646 (1.150-6.091) |
|
Breast surgery
Mastectomy Quadrantectomy/lumpectomy |
55.5 (0.06) 68.4 (0.05) |
32 (21-43) NR |
0.06 | 1.518 (0.973-2.367) |
|
Axillary surgery
Axillary dissection Sentinel node biopsy |
51.3 (0.05) 79.7 (0.05) |
28 (15-40) NR |
0.0001 | 2.813 (1.647-4.804) |
| N:129 | ||||
| 43.4 (0.04) | 16 (7-24) | |||
|
Nodal status
Positive Negative |
27.4 (0.05) 65.4 (0.06) |
9 (6-12) NR |
<0.0001 | 2.788 (1.720-4.519) |
|
Size of residual breast disease
ypT3/4 ypT1/2 |
21.4 (0.11) 46.7 (0.05) |
5 (1-8) 18 (7-29) |
0.01 | 2.283 (1.201-4.340) |
|
Grading
3 1/2 |
40.1 (0.05) 66.7 (0.12) |
13 (9-18) NR |
0.07 | 2.279 (0.921-5.639) |
|
Ki67
>20 ≤20 |
42.4 (0.05) 57.1 (0.13) |
16 (8-24) NR |
0.25 | 1.627 (0.708-3.741) |
|
Breast surgery
Mastectomy Quadrantectomy/lumpectomy |
34.8 (0.06) 52.4 (0.06) |
11 (6-15) NR |
0.03 | 1.647 (1.056-2.567) |
|
Axillary surgery
Axillary dissection Sentinel node biopsy |
33.6 (0.05) 65.0 (0.08) |
11 (8-13) NR |
0.002 | 2.300 (1.344-3.936) |
N, number; yr: year; SE, standard error; mDFS, median disease free survival (months); CI, confidence interval; HR, hazard ratio; NR, not reached.